TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SW6UGD7

Real-time Boerse Frankfurt Warrants 14:40:40 26/06/2024 BST
2.98 EUR -1.00% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month+46.83%
1 month+40.65%
Date Price Change
26/06/24 2.98 -1.00%
25/06/24 3.01 -0.33%
24/06/24 3.02 +3.42%
21/06/24 2.92 -1.35%
20/06/24 2.96 +3.50%

Real-time Boerse Frankfurt Warrants

Last update June 26, 2024 at 02:40 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SW6UGD
ISINDE000SW6UGD7
Date issued 17/05/2024
Strike 53.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.28
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.11
Lowest since issue 1.94
Spread 0.01
Spread %0.34%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
84.97 USD
Average target price
108.1 USD
Spread / Average Target
+27.21%
Consensus